APA

Patel T. A., Ensor J. E., Creamer S. L., Boone T., Rodriguez A. A., Niravath P. A., Darcourt J. G., Meisel J. L., Li X., Zhao J., Kuhn J. G., Rosato R. R., Qian W., Belcheva A., Schwartz M. R., Kaklamani V. G. & Chang J. C. (20200226). A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). : Breast cancer research : BCR.

Chicago

Patel Tejal A, Ensor Joe E, Creamer Sarah L, Boone Toniva, Rodriguez Angel A, Niravath Poly A, Darcourt Jorge G, Meisel Jane L, Li Xiaoxian, Zhao Jing, Kuhn John G, Rosato Roberto R, Qian Wei, Belcheva Anna, Schwartz Mary R, Kaklamani Virginia G and Chang Jenny C. 20200226. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). : Breast cancer research : BCR.

Harvard

Patel T. A., Ensor J. E., Creamer S. L., Boone T., Rodriguez A. A., Niravath P. A., Darcourt J. G., Meisel J. L., Li X., Zhao J., Kuhn J. G., Rosato R. R., Qian W., Belcheva A., Schwartz M. R., Kaklamani V. G. and Chang J. C. (20200226). A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). : Breast cancer research : BCR.

MLA

Patel Tejal A, Ensor Joe E, Creamer Sarah L, Boone Toniva, Rodriguez Angel A, Niravath Poly A, Darcourt Jorge G, Meisel Jane L, Li Xiaoxian, Zhao Jing, Kuhn John G, Rosato Roberto R, Qian Wei, Belcheva Anna, Schwartz Mary R, Kaklamani Virginia G and Chang Jenny C. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). : Breast cancer research : BCR. 20200226.